Dragonfly Therapeutics Appoints Head of Clinical Development

Doing deals in a time of coronavirus

AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player

Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

Dragonfly Therapeutics in $695M cancer R&D pact with Merck

Merck’s cancer R&D juggernaut ties up to little Dragonfly’s natural born killer platform

Merck & Co. Partners with Dragonfly on NK-Based Cancer Immunotherapies

Dragonfly and Merck Strike $695 Million Deal for Solid Tumors

The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

Dragonfly Founders to Lead Disruptors Conversation at Boston Biotech

Celgene bags option on NK cell-based blood cancer assets

Dragonfly, Tyler Jacks’s Disney-Backed Startup, Gets $33M in Celgene Deal